The determination to effect the workforce reduction was made in connection with the Company's decision to terminate its REBUILD Phase 3 clinical study of INOpulse for the treatment of fibrotic Interstitial Lung Disease ("fILD") and withdraw patients from the Company's ongoing INOpulse development programs.The Company intends to enter into separation and/or transition agreements with each of Peter Fernandes, the Company's Chief Executive Officer, Parag Shah, the Company's Vice President of Business Operations, and Martin Dekker, the Company's Vice President of Engineering and Manufacturing.
On June 24, 2023, Bellerophon Therapeutics Approved Reduction-In-Force Of Substantially All Of Its Employees, Including Its Executive Officers - Filing
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.